Acquisition of BioCell Lugano, Switzerland

FamiCord Group acquired BioCell Lugano, which includes a modern laboratory in Switzerland. This is another important step towards expanding the scope of activities in western Europe, further enhancing FamiCord’s ability to offer innovative stem cell banking and regenerative medicine solutions across the continent.

The laboratory developed and started to commercialize technology of banking perinatal tissues such as placental villi and amniotic fluid cells. FamiCord plans to further expand BioCell Lugano laboratory capabilities, which currently serves B2B clients in Italy and Egypt. Company plans to expand this activity to offer cord blood banking which currently is not in the scope of BioCell services.

Recently added

02 April 2026 Autism Awareness Day: First FamiCord EAP Therapies Launched for ASD Patients Read more
17 November 2025 FamiCord Group Recognized as Europe’s Leading Stem Cell Bank FamiCord is the largest stem cell bank in Europe and the third largest in the world. The quality of its services is validated by international certifications, and the company has now been recognized as Europe’s Leading Stem Cell Bank by Life Sciences Review, highlighting its commitment to excellence, clinical reliability, and innovation in stem cell banking.FamiCord Group have been awarded as “The Europe’s Leading Stem Cell Bank” , independent experts jury underlined FamiCord has established itself as a leading provider in the field, guiding families through the collection, processing, and long-term preservation of cord blood and perinatal tissues. Read more